中国临床药理学杂志2016，Vol.32Issue(7)：615-617,3.DOI:10.13699/j.cnki.1001-6821.2016.07.013
吉西他滨联合厄洛替尼对晚期胰腺癌的临床疗效研究
Clinical effect of gemcitabine combined with erlotinib on advanced pancreatic cancer
沈俊 1周锐 1王建祥1
作者信息
- 1. 华中科技大学 同济医学院 附属普爱医院 综合外科，湖北武汉 430032
- 折叠
摘要
Abstract
Objective To investigate the clinical effect of gemcitabine combined with erlotinib in the treatment of advanced pancreatic cancer, and provide more information for the second-line treatment of this dis-ease.Methods A total of 112 patients of advanced pancreatic cancer were randomly divided into treatment group and control group, 56 cases in each group.Patients in control group were given monotherapy of gem-citabine 1000 mg· m-2 for 30 min, one dose in a week, and 3 weeks a cycle, and treated at least 2 cycles.Patients in treatment group were treated with gemcitabine and erlotinib.The dosing plan of gemcitabine was just as control group, and on day 1 and 8 in every cycle the patients were given the treatment of erlotinib 100-150 mg· d-1 , 21 d a cycle, and treated at least 2 cycles.The clinical effects including total clinical effective rate, the clinical benefit effect and the adverse drug reactions were evaluated.Results The total clinical effective rate of treatment group was 66.1%, which was significantly higher than that of control group of 39.3% ( P<0.05 ).The clinical benefit rate was 71.4% in treatment group and 44.6%in control group, with statistically significant difference ( P<0.05 ).The incidence of myelosuppression and gastroin-testinal reactions had no significant difference between two groups ( P>0.05).Conclusion It had significant clinical effec t of gemcitabinecombined with erlotinib in the treatment of advanced pancreatic cancer, the total clinical effect rate and clinical benefit rate were improved significantly, but without more adverse reactions.关键词
吉西他滨/厄洛替尼/胰腺癌Key words
gemcitabine/erlotinib/advanced pancreatic cancer分类
医药卫生引用本文复制引用
沈俊,周锐,王建祥..吉西他滨联合厄洛替尼对晚期胰腺癌的临床疗效研究[J].中国临床药理学杂志,2016,32(7):615-617,3.
